High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer

Keyphrases

• High Risk 100%
• ER-positive 100%
• High-level Expression 100%
• ER+ Breast Cancer 100%
• RET Receptor Tyrosine Kinase 100%
• Risk Subset 100%
• Tumor 80%
• Clinical Trials 40%
• Poor Outcome 40%
• Resistance to Endocrine Therapy 40%
• Clinically Significant 20%
• Estrogen 20%
• Phosphoinositide 3-kinase (PI3K) 20%
• Tyrosine Kinase Inhibitor 20%
• MRNA Expression 20%
• Clinical High Risk 20%
• Clinical Response 20%
• Primary Tumor 20%
• Expression Data 20%
• Luminal Breast Cancer 20%
• Overall Survival 20%
• Antiestrogen 20%
• Disease-free Survival 20%
• Druggability 20%
• Progression-free Survival 20%
• Treatment Failure 20%
• Kaplan-Meier 20%
• Gene Set 20%
• Disease-specific Survival 20%
• Cancer Genome Atlas 20%
• 75th Percentile 20%
• Breast Invasive Carcinoma 20%
• Pan-cancer 20%
• Differential Gene Expression Analysis 20%
• Adaptive Resistance 20%
• Gene Signature 20%
• Bad Outcomes 20%
• Transcriptomic Data 20%
• Targetable 20%

Medicine and Dentistry

• Protein Tyrosine Kinase 100%
• Estrogen Receptor Positive Breast Cancer 100%
• Glial Cell Line Derived Neurotrophic Factor 100%
• Tumor 80%
• Clinical Trial 40%
• Breast Cancer 40%
• Hormone Therapy 40%
• Gene Expression Profiling 40%
• Biological Marker 20%
• Antiestrogen 20%
• Primary Tumor 20%
• Transcriptomics 20%
• Overall Survival 20%
• Progression Free Survival 20%
• Disease Free Survival 20%
• Disease Specific Survival 20%
• Tyrosine-Kinase Inhibitor 20%
• Differential Gene Expression 20%
• Invasive Carcinoma 20%
• The Cancer Genome Atlas 20%
• Messenger RNA 20%
• Estrogen 20%